Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
| Autor: | Leonid B. Reshko, Jeremy Gaskins, Craig L. Silverman, Neal Dunlap |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
SBRT Performance status Adrenal gland business.industry Nausea Retrospective cohort study oligometastatic disease medicine.disease Primary tumor Effective dose (radiation) oligoprogressive disease medicine.anatomical_structure stereotactic body radiotherapy Oncology medicine Radiology Nuclear Medicine and imaging Radiology medicine.symptom Stage (cooking) Neutrophil to lymphocyte ratio business metastatic disease Research Paper adrenal metastases |
| Zdroj: | Reports of Practical Oncology and Radiotherapy |
| ISSN: | 2083-4640 1507-1367 |
| DOI: | 10.5603/rpor.a2021.0055 |
| Popis: | BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality. The aim of the study was to evaluate the safety and efficacy of adrenal gland SBRT in oligometastatic and oligoprogressive disease. MATERIALS AND METHODS: In this retrospective study, we performed a single-institution analysis of 26 adrenal lesions from 23 patients with oligometastatic or oligoprogressive disease treated from 2013 to 2019 with the goal of achieving durable local control. Palliative cases were excluded. Radiation dosimetry data was collected. Kaplan Meier product estimator and Cox proportional hazards regression analysis were used for statistical analysis. RESULTS: The median dose was 36 Gy in 3 fractions (range: 24–50 Gy and 3–6 fractions) with a median biologically effective dose (BED10) of 72 (range: 40–100). 1-year local control rate was 80% and median local control was not achieved due to a low number of failures. 1- and 2-year overall survival rates were 66% and 32%. Toxicity was mild with only one case of grade 2 nausea and no grade 3–5 toxicity. Higher neutrophil to lymphocyte ratio was associated with worse overall survival and a trend toward worse progression-free survival. In addition, worse performance status and lower BED10 were associated with worse survival. No such association could be shown for primary tumor location, histology, size or stage. CONCLUSION: Adrenal SBRT for oligometastatic or oligoprogressive disease is a safe and effective form of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|